Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.75 GBX | +4.88% | -2.27% | +9.14% |
04-05 | RUA Life Sciences expects flat annual revenue on strong second half | AN |
04-05 | RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 | CI |
Sales 2024 * | 2.24M 2.8M 224M | Sales 2025 * | 3.28M 4.1M 328M | Capitalization | 6.67M 8.33M 667M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.25M -100M | Net income 2025 * | - 0 0 | EV / Sales 2024 * | 1.34 x |
Net cash position 2024 * | 3.66M 4.57M 366M | Net cash position 2025 * | 2.95M 3.68M 295M | EV / Sales 2025 * | 1.14 x |
P/E ratio 2024 * |
-2.48
x | P/E ratio 2025 * |
-7.17
x | Employees | 48 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.93% |
Latest transcript on RUA Life Sciences plc
1 day | +4.88% | ||
1 week | -2.27% | ||
Current month | +19.44% | ||
1 month | +17.49% | ||
3 months | -12.60% | ||
6 months | -12.24% | ||
Current year | +9.14% |
Managers | Title | Age | Since |
---|---|---|---|
Lachlan Smith
DFI | Director of Finance/CFO | - | 30/11/21 |
Bill Brown
CHM | Chairman | 55 | 20/10/11 |
John McKenna
BRD | Director/Board Member | 71 | 30/10/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Brown
CHM | Chairman | 55 | 20/10/11 |
John Louis Ely
BRD | Director/Board Member | 73 | - |
Director/Board Member | 57 | 17/01/21 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 10.75 | +4.88% | 535,404 |
25/04/24 | 10.25 | 0.00% | 246,695 |
24/04/24 | 10.25 | -4.65% | 577,459 |
23/04/24 | 10.75 | 0.00% | 53,279 |
22/04/24 | 10.75 | -2.27% | 276,581 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.14% | 8.31M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- AOR Stock